Pharmafile Logo
Pharmafocus logo
Advanced Search

opdivo

Showing 15 posts of 108 posts found.

Opdivo launched in the UK for skin cancer

July 2, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer

Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …

News

BMS’ Opdivo accepted to UK early access scheme

June 30, 2015
Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo

Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …

News
yervoy image

BMS immunotherapy combination impresses at ASCO

June 1, 2015
Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo

Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …

News
Opdivo

BMS’ Opdivo improves lung cancer survival

May 29, 2015
Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo

A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …

News
Opdivo

EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

News
Pfizer image

Merck KGaA and Pfizer alliance begins lung cancer study

April 21, 2015
Research and Development, Sales and Marketing Merck KGaA, Pfizer, avelumab, keytruda, oncology, opdivo

Merck KGaA and Pfizer have enrolled and treated the first patient in a late-stage study of their anti-PD1 cancer immunotherapy …

News
BMS image

BMS’ Opdivo wins US lung cancer race

March 5, 2015
Research and Development, Sales and Marketing BMS, Prostvac, biosciences, flexus, lung cancer, oncology, opdivo

The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …

News
Giovanni Caforio image

BMS names operating officer as new chief executive

January 21, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Giovanni Caforio, Lamberto Andreotti, Yervoy, opdivo

Bristol-Myers Squibb’s chief operating officer Giovanni Caforio will be stepping in to Lamberto Andreotti’s shoes as chief executive from May …

News

BMS Opdivo trial scores early goal

January 14, 2015
Research and Development, Sales and Marketing BMS, Merck, cancer nsclc, keytruda, nivolumab, opdivo

A late-stage trial of Bristol-Myers Squibb’s lung cancer drug Opdivo has been stopped early after showing promising results – but …

News
Lilly image

Lilly, BMS and Merck unite for cancer trials

January 13, 2015
Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo

Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …

News

Pharma industry set for bumper 2015

January 5, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2015, FDA, bumper, harvoni, opdivo, pharma, sovaldi

Industry analysts predict 2015 will be another year of growth for the pharma, after approvals of new drugs soared to …

News
Cyramza image

Lilly’s lung cancer drug sees FDA approval

December 17, 2014
Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab

Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …

News

Pfizer signs $3 billion cancer deal

November 18, 2014
Research and Development, Sales and Marketing Cancer, Merck KGaA, PD-L1, Pfizer, anti-PD-L1, opdivo

Pfizer has signed a multi-billion dollar deal to develop one of Merck KGaA’s investigational drugs, MSB0010718C, an anti-PD-L1 antibody. The …

News
Lonza image

BMS and Lonza announce expansion plans

October 31, 2014
Manufacturing and Production, Sales and Marketing BMS, Lonza, Orencia, manufacturing, opdivo

Bristol-Myers Squibb (BMS) and Lonza are to expand upon an existing manufacturing agreement to meet anticipated demand for commercial biologics. …

News
The study will be conducted by Janssen image

BMS, Pharmacyclics and Janssen collaborate on cancer

October 14, 2014
Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo

Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025